A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas Article

Dixit, Karan S, Sachdev, Sean, Amidei, Christina et al. (2021). A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas . JOURNAL OF NEURO-ONCOLOGY, 155(3), 297-306. 10.1007/s11060-021-03875-8

cited authors

  • Dixit, Karan S; Sachdev, Sean; Amidei, Christina; Kumthekar, Priya; Kruser, Tim J; Gondi, Vinai; Grimm, Sean; Lukas, Rimas; Nicholas, Martin Kelly; Chmura, Steven J; Fought, Angela J; Mehta, Minesh; Raizer, Jeffrey J

sustainable development goals

authors

publication date

  • October 24, 2021

webpage

published in

keywords

  • Bevacizumab
  • CHEMOTHERAPY
  • COMBINATION
  • Clinical Neurology
  • DOSE-INTENSE TEMOZOLOMIDE
  • GLIOBLASTOMA
  • Glioblastoma
  • LARGE-VOLUME REIRRADIATION
  • Life Sciences & Biomedicine
  • Neurosciences & Neurology
  • Oncology
  • PHASE-II TRIAL
  • PROGRESSION
  • Radiation
  • Re-irradiation
  • Recurrent glioma
  • SALVAGE REIRRADIATION
  • SINGLE-AGENT BEVACIZUMAB
  • STEREOTACTIC RADIOTHERAPY
  • Science & Technology
  • Temozolomide

Digital Object Identifier (DOI)

publisher

  • SPRINGER

start page

  • 297

end page

  • 306

volume

  • 155

issue

  • 3